Adalimumab Efficacy in Hidradenitis Suppurativa Patients is Sustained at Least Three Years with Weekly Dosing: Results from a Phase 3 Open-Label Extension Study (PIONEER). J of Skin [Internet]. 2017 Oct. 27 [cited 2025 Apr. 10];1(3.1):s128. Available from: https://skin.dermsquared.com/skin/article/view/81